Re: Guymer et al.: Subthreshold nanosecond laser intervention in age-related macular degeneration: The LEAD Randomized Controlled Clinical Trial (Ophthalmology. 2019;126:829-838) Reply
Robyn H Guymer, Zhichao Wu, Fred K Chen, Usha Chakravarthy, Jennifer J Arnold, Wilson J Heriot, Shane R Durkin, Chi D Luu
OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2019
Awarded by National Health & Medical Research Council of Australia
Supported by National Health & Medical Research Council of Australia (project grant no.: APP1027624 [R.H.G. and C.D.L.], and fellowship grant no.: GNT1103013 (R.H.G.), APP1104985 [Z.W.], APP1054712 [F.K.C.] and APP1142962 [F.K.C.]), and BUPA Health Foundation (Australia) (R.H.G. and C.D.L.). CERA receives operational infrastructure support from the Victorian Government. Ellex R&D Pty Ltd (Adelaide, Australia) provided partial funding of the central coordinating center and the in-kind provision of Ellex 2RTTM laser systems, ongoing support of those systems and the Macular Integrity Assessment microperimeters for the duration of the study. The web-based Research Electronic Data Capture (REDCap) application and open-source platform OpenClinica allowed secure electronic data capture. The study is sponsored by the Centre for Eye Research Australia (CERA), an independent medical research institute and a not-for-profit company.